Evidence map›Paper›PMID 30678184›Full record

ArticleNutrients2019

Evidence that Nitric Oxide is Involved in the Blood Pressure Lowering Effect of the Peptide AVFQHNCQE in Spontaneously Hypertensive Rats.

Anna Mas-Capdevila, Lisard Iglesias-Carres, Anna Arola-Arnal, Gerard Aragonès, Amaya Aleixandre, Francisca I Bravo, Begoña Muguerza

Open access · goldAbstract read
In one paragraph

Article in Nutrients, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.9field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Molecular mechanism ofChinese herbal medicines · 2021
    Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Anna Mas-CapdevilaNutrigenomics Research Group, Department of Biochemistry and Biotechnology, Universitat Rovira i Virgili, 43007 Tarragona, Spain. anna.mas@urv.cat.
Lisard Iglesias-CarresNutrigenomics Research Group, Department of Biochemistry and Biotechnology, Universitat Rovira i Virgili, 43007 Tarragona, Spain. lisard.iglesias@urv.cat.ORCID 0000-0003-0768-0611
Anna Arola-ArnalNutrigenomics Research Group, Department of Biochemistry and Biotechnology, Universitat Rovira i Virgili, 43007 Tarragona, Spain. anna.arola@urv.cat.ORCID 0000-0001-6529-1345
Gerard AragonèsNutrigenomics Research Group, Department of Biochemistry and Biotechnology, Universitat Rovira i Virgili, 43007 Tarragona, Spain. gerard.aragones@urv.cat.ORCID 0000-0001-8657-5726
Amaya AleixandreDepartment of Pharmacology, School of Medicine, Universidad Complutense de Madrid, 280040 Madrid, Spain. amaya@med.ucm.es.
Francisca I BravoNutrigenomics Research Group, Department of Biochemistry and Biotechnology, Universitat Rovira i Virgili, 43007 Tarragona, Spain. franciscaisabel.bravo@urv.cat.ORCID 0000-0002-6468-3088
Begoña MuguerzaNutrigenomics Research Group, Department of Biochemistry and Biotechnology, Universitat Rovira i Virgili, 43007 Tarragona, Spain. begona.muguerza@urv.cat.ORCID 0000-0001-7384-8588
Universitat Rovira i Virgili · ESTechnological Center of Nutrition and Health · ESUniversidad Complutense de Madrid · ES

Funding

Ministerio de Economía, Industria y Competitividad, Gobierno de España AGL-2013-40707-RMinisterio de Economía, Industria y Competitividad, Gobierno de España AGL-2016-77105-R
6 · The paper itself

Abstract

AVFQHNCQE is an antihypertensive nonapeptide obtained from a chicken foot protein hydrolysate. The present study aims to investigate the mechanisms involved in its blood pressure (BP)-lowering effect. Male (17⁻20 weeks old) spontaneously hypertensive rats (SHR) were used in this study. Rats were divided into two groups and orally administered water or 10 mg/kg body weight (bw) AVFQHNCQE. One hour post-administration, animals of both groups were intra-peritoneally treated with 1 mL of saline or with 1 mL of saline containing 30 mg/kg bw Nω-nitro-L-arginine methyl ester (L-NAME), an inhibitor of nitric oxide (NO) synthesis, or with 1 mL of saline containing 5 mg/kg bw indomethacin, which is an inhibitor of prostacyclin synthesis (

Indexed as

Amino Acid SequenceAnimalsAntihypertensive AgentsAortaEndothelium, VascularGene Expression RegulationMaleMalondialdehydeNitric OxidePeptidesRatsRats, Inbred SHRRats, Sprague-DawleyRNAAntihypertensive AgentsMalondialdehydeNitric OxidePeptidesRNAbioactive peptidebioactivityblood pressureendothelial dysfunctionnitric oxidespontaneously hypertensive rats

Identifiers

PMID30678184
PMCPMC6412221
OpenAlexW2911836212

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.